Can nexium keep Kids' esophagitis at bay? new study seeks answers

NCT ID NCT05267613

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This phase 3 study tests two doses of Nexium (esomeprazole) in 53 children aged 1 to 11 years who have erosive esophagitis, a condition where stomach acid damages the esophagus. The goal is to see which dose better maintains healing after an initial 8-week treatment period. Children take the medicine daily for 16 weeks, and doctors check healing with a scope at the end.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nexium (esomeprazole)
What this could lead to: If successful, this could confirm a safe and effective dose of Nexium to prevent erosive esophagitis from coming back in young children.
What could go wrong: This is a small, early-phase study with only 53 children, so results may not apply to all kids. Long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophagitis gastroesophageal reflux disease peptic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EROSIVE ESOPHAGITIS

Contacts and locations

Locations

Research Site

Mobile, Alabama, 36604, United States
Research Site

Sacramento, California, 95817, United States
Research Site

Miami, Florida, 33122, United States
Research Site

Miami, Florida, 33155, United States
Research Site

Orlando, Florida, 32806, United States
Research Site

Carmel, Indiana, 46290, United States
Research Site

Shreveport, Louisiana, 71103, United States
Research Site

The Bronx, New York, 10468, United States
Research Site

Akron, Ohio, 44308, United States
Research Site

Cleveland, Ohio, 44195, United States
Research Site

Milwaukee, Wisconsin, 53226, United States
Research Site

Córdoba, 5000, Argentina
Research Site

Córdoba, X5016KEH, Argentina
Research Site

Paraná, 3100, Argentina
Research Site

Rosario, S2000DEJ, Argentina
Research Site

Clayton, 3168, Australia
Research Site

Namur, 5101, Belgium
Research Site

Athens, 11527, Greece
Research Site

Thessaloniki, 54642, Greece
Research Site

Thessaloniki, 56249, Greece
Research Site

Messina, 98124, Italy
Research Site

Naples, 80131, Italy
Research Site

Naples, 80138, Italy
Research Site

Roma, 00137, Italy
Research Site

Roma, 00161, Italy
Research Site

Vilnius, LT-08406, Lithuania
Research Site

Coimbra, 3000-602, Portugal
Research Site

Lisbon, 1169-045, Portugal
Research Site

Lisbon, 1500-650, Portugal
Research Site

Lisbon, 1998-018, Portugal
Research Site

Porto, 4099-001, Portugal
Research Site

Porto, 4200-319, Portugal
Research Site

Viana do Castelo, 4901-858, Portugal
Research Site

Badalona, 08916, Spain
Research Site

Santiago de Compostela, 15706, Spain
Research Site

Seville, 41009, Spain
Research Site

Seville, 41013, Spain
Research Site

Hanoi, 100000, Vietnam
Research Site

Hanoi, 10000, Vietnam
Research Site

Hà Nội, 100000, Vietnam
Research Site

Hochiminh, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.